Merck: Keytruda meets goal in late-stage clinical trial
(CercleFinance.com) - A late-stage trial of Merck's Keytruda found that the immunotherapy drug demonstrated a statistically significant improvement in the pathological complete response rate for the treatment of triple-negative breast cancer, the company said.
A Phase 3 trial investigating Merck's anti-PD-1 therapy, in combination with chemotherapy, met one of the dual-primary endpoints of pathological complete response (pCR) in patients with triple-negative breast cancer (TNBC).
A pathological complete response - or pCR - is defined as a lack of all signs of cancer in tissue samples analysed after the completion of therapy and surgery, Merck said.
TNBC is an aggressive malignancy with a high rate of recurrence within the first five years of diagnosis.
The Merck share is currently up 0.8% in New York.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
A Phase 3 trial investigating Merck's anti-PD-1 therapy, in combination with chemotherapy, met one of the dual-primary endpoints of pathological complete response (pCR) in patients with triple-negative breast cancer (TNBC).
A pathological complete response - or pCR - is defined as a lack of all signs of cancer in tissue samples analysed after the completion of therapy and surgery, Merck said.
TNBC is an aggressive malignancy with a high rate of recurrence within the first five years of diagnosis.
The Merck share is currently up 0.8% in New York.
Copyright (c) 2019 CercleFinance.com. All rights reserved.